Earnings ·
Silexion Therapeutics Corp reported second-quarter and six-month financial results ending June 30, 2026
SLXNWSilexion Therapeutics Corp
Silexion Therapeutics Corp reported second-quarter and six-month financial results ending June 30, 2026. The company incurred a net loss of $3.6 million for the quarter and $6.3 million for the six-month period, driven by increased research and development expenses related to its Phase 2/3 clinical trial preparations. R&D expenses rose 120% year-over-year to approximately $2.2 million in Q2. The company closed a public offering on August 13, 2026, raising gross proceeds of approximately $2.5 million and net proceeds of $2.1 million. Silexion also announced the successful initiation of its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center in July 2026, following regulatory approvals in Israel and Germany. The company states it has restored compliance with Nasdaq’s shareholders’ equity listing requirement. Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers.